Cancer

News

Janssen J&J Johnson and Johnson pharmaceutical companies

EU regulators to fast-track Janssen's multiple myeloma CAR-T

European regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage trial results.

News

Fusion raises $105m for radiopharmaceutical trials

Radiopharmaceuticals are already well established in imaging technology for a range of diseases – but their use to deliver a lethal dose of radiation to cancer cells is also gaining increas

News

Clovis' Rubraca is latest PARP drug showing promise in pancr...

Clovis Oncology’s Rubraca has become the latest PARP drug to show potential in pancreatic cancer, as pharma companies seek new uses outside ovarian cancer where this class first gained a fo

News

NICE recommends interim funding for Lilly's breast cancer dr...

Final draft guidance from NICE has recommended interim NHS funding for Eli Lilly’s Verzenios (abemaciclib) with fulvestrant, giving certain breast cancer patients an option that can delay c

News

AZ signs multi-billion cancer R&D deal with Daiichi Sankyo

AstraZeneca is to raise $3.5 billion to fund a global development and marketing collaboration with Daiichi Sankyo, for an antibody-drug conjugate and potential new targeted cancer medicine,

News

AZ gets NICE nod for ‘big advance’ Imfinzi in lung cancer

AstraZeneca has won the backing of NICE for its cancer immunotherapy Imfinzi for non-small cell lung cancer (NSCLC), with the drug made available via the Cancer Drugs Fund for now.

EU regulators to fast-track Janssen's multiple myeloma CAR-T

Fusion raises $105m for radiopharmaceutical trials

Clovis' Rubraca is latest PARP drug showing promise in pancr...

NICE recommends interim funding for Lilly's breast cancer dr...

AZ signs multi-billion cancer R&D deal with Daiichi Sankyo

AZ gets NICE nod for ‘big advance’ Imfinzi in lung cancer

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Cancer

Editor's Picks